RecruitingPhase 1NCT07101328

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

BAF_FRontier-1, A First-in-Human, Phase 1 Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-cell Activation Factor Receptor (BAFF-R) T-Cell Engager Bispecific Antibody in Adult Participants With Previously Treated B-cell Malignancies

Sponsor

Eli Lilly and Company

Enrollment

215 participants

Start Date

May 28, 2026

Study Type

INTERVENTIONAL

Conditions

Lymphoma, Non-Hodgkin B-cell Lymphoma Waldenstrom Macroglobulinemia Lymphoma, Mantle-Cell Lymphoma, Follicular Lymphoma, Large B-Cell, Diffuse Lymphoma, B-cell Marginal Zone

Summary

The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called LY4152199 - IV for people with b-cell lymphoma, lymphoma, b-cell marginal zone, and other related conditions. The study is currently recruiting participants at 50 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLY4152199 - IV

Administered by IV infusion

Locations(50)

City of Hope

Duarte, California, United States

University of Colorado Denver - School of Medicine - Anschutz Medical Campus

Aurora, Colorado, United States

Colorado Blood Cancer Institute

Denver, Colorado, United States

Yale University School of Medicine - Yale Cancer Center

New Haven, Connecticut, United States

The University of Chicago Medical Center (UCMC)

Chicago, Illinois, United States

University of Iowa

Iowa City, Iowa, United States

University of Kansas Cancer Center

Kansas City, Kansas, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, United States

Mayo Clinic - Rochester

Rochester, Minnesota, United States

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, United States

New York University (NYU) Clinical Cancer Center

New York, New York, United States

Weill Cornell Medicine

New York, New York, United States

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

New York, New York, United States

Cleveland Clinic

Cleveland, Ohio, United States

University of Pennsylvania Abramson Cancer Center

Philadelphia, Pennsylvania, United States

SCRI Oncology Partners

Nashville, Tennessee, United States

University of Texas Southwestern

Dallas, Texas, United States

MD Anderson Cancer Center

Houston, Texas, United States

Intermountain Healthcare

Salt Lake City, Utah, United States

Swedish Cancer Institute (SCI)

Seattle, Washington, United States

Froedtert Hospital and the Medical College of Wisconsin

Milwaukee, Wisconsin, United States

The Alfred Hospital

Melbourne, VIC, Australia

Linear Clinical Research

Nedlands, Australia

Lady Davis Institute for Medical Research Jewish General Hospital

Montreal, Canada

University Health Network (UHN) - Princess Margaret Cancer Centre

Toronto, Canada

BC Cancer - Vancouver

Vancouver, Canada

Aarhus University Hospital

Aarhus, Denmark

Center for Cancer and Organ Diseases - Rigshospitalet

Copenhagen, Denmark

CHU de Lille - Hopital Claude Huriez

Lille, France

AP-HP Hopital Saint-Louis

Paris, France

Charite Universitaetsmedizin Berlin

Berlin, Germany

LMU Klinikum Muenchen-Campus Grosshadern

München, Germany

Universitaetsklinikum Muenster

Münster, Germany

IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola

Bologna, Italy

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale

Naples, Italy

Istituto Clinico Humanitas

Rozzano, Italy

National Cancer Center Hospital East

Chiba, Japan

Okayama University Hospital

Okayama, Japan

The Cancer Institute Hospital of JFCR

Tokyo, Japan

Pratia MCM Krakow

Krakow, Poland

AIDPORT Sp. z o.o.

Skorzewo, Poland

Seoul National University Hospital

Seoul, South Korea

Asan Medical Center

Seoul, South Korea

Hospital Universitario Vall d'Hebron

Barcelona, Spain

Institut Catala d'Oncologia - L'Hospitalet

Barcelona, Spain

South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz

Madrid, Spain

Leeds Teaching Hospitals NHS Trust

Leeds, United Kingdom

Oxford University Hospitals NHS Foundation Trust

Oxford, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07101328

Related Trials

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

NCT0663458950 locations

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

NCT06742996155 locations

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

NCT0708280314 locations

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

NCT009235071 location

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

NCT06890884138 locations